Zepbound growth has outpaced Wegovy in recent months, and sales quadrupled to $2.31 billion in the first three months of this year compared to the same period of 2024, while Mounjaro more than ...

With the notable exceptions of Novo Nordisk A/S (NYSE: NVO) and Eli Lilly & Co. (NYSE: LLY), biotechnology stocks had a rough ...

The predictions of a slowdown in demand could stem in part from the ascendancy of rival therapies from Eli Lilly based on tirzepatide – Mounjaro for diabetes and obesity therapy Zepbound – as ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three ...

Bernstein SocGen Group reiterated an Outperform rating and $1,100.00 price target on Eli Lilly (NYSE: LLY) stock Monday, citing continued strong performance of its weight loss medication Zepbound.

Sales estimates for Eli Lilly & Company (NYSE:LLY)’s weight-loss treatment Zepbound may surpass market expectations by about 15%, according to the investment bank’s analysis, while estimates ...

Bernstein SocGen Group reiterated an Outperform rating and $1,100.00 price target on Eli Lilly (NYSE: LLY) stock Monday, citing continued strong performance of its weight loss medication Zepbound.